NCT03066206 2026-02-20
Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC
M.D. Anderson Cancer Center
Phase 2 Terminated
Clinical Trials
4 trialsNCT05045404 2023-09-13
Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02979821 2018-05-24
Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)
Korean Association for the Study of Targeted Therapy
Phase 2 Completed
NCT01819428 2016-03-01
NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma
National OncoVenture
Phase 2 Terminated